Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor

Stock Track

04/15

Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.

The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.

This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1194083813"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194083813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194083813?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 09:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194083813","market":"sg","top_or_hot":-1,"title":"Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor","media":"Stock Track","content":"<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.</p><p>The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.</p><p>This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Genfleet Therapeutics-B Soars 5.48% Intraday on Breakthrough Therapy Designation for KRAS G12D Inhibitor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 09:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.</p><p>The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.</p><p>This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02595","symbol_name":"劲方医药-B","start_time":0,"source_url":"","article_id":"1194083813","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194083813","pubTimestamp":1776217187,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02595":"劲方医药-B"},"translate_title":"个股追踪|Genfleet Therapeutics-B盘中大涨5.48%KRAS G12D抑制剂获突破性疗法认定","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02595":1},"content_text":"Genfleet Therapeutics-B (02595.HK) saw its stock price soar 5.48% during intraday trading on Wednesday, extending its recent positive momentum.The surge follows the company's announcement that its oral KRAS G12D (ON/OFF) inhibitor GFH375 has been included in the Breakthrough Therapy Designation (BTD) list by China's Center for Drug Evaluation of the National Medical Products Administration. This designation is intended for the monotherapy treatment of KRAS G12D-mutant metastatic patients who have received at least one prior systemic therapy.This marks the first KRAS G12D inhibitor monotherapy to receive BTD recognition in China and represents the second BTD obtained by GFH375, reinforcing its differentiated positioning in the competitive KRAS-targeted therapy landscape. As a clinical-stage biotech firm focused on oncology, Genfleet's valuation is primarily driven by pipeline progression, making this regulatory milestone a significant positive catalyst.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}